NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
Neonc Technologies, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
Arcus Biosciences, Inc.
ImmunityBio, Inc.
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Sumitomo Pharma America, Inc.
Hoffmann-La Roche
CStone Pharmaceuticals